GlassScriptPhysician profile
Gregory K Terpstra
NPI 1952399792
$588.78
in general payments reported to CMS, 2019-2025
14 companies · $19.49 in 2025
The $19.49 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $13.63 · 2021: $106 · 2022: $57.44 · 2023: $314 · 2024: $77.33 · 2025: $19.49.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $403 · Education: $8.45.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $402.81 |
| Education | $8.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $265.25 | 2023 | Vraylar |
| Currax Pharmaceuticals LLC | $55.72 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $52.43 | 2022-2023 | |
| Apria Healthcare LLC | $48.60 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $27.67 | 2024 | Rexulti |
| Vanda Pharmaceuticals INC. | $19.49 | 2025 | Fanapt |
| Lilly USA, LLC | $18.63 | 2024 | Mounjaro |
| Dexcom, INC. | $16.52 | 2024 | Dexcom G6 Transmitter |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.06 | 2021 | |
| Glaxosmithkline, LLC. | $14.51 | 2024 | Arexvy, Trelegy Ellipta |
| Exact Sciences Corporation | $14.24 | 2023 | Cologuard Collection Kit |
| Arbor Pharmaceuticals, INC. | $14.03 | 2021 | |
| Janssen Pharmaceuticals, INC | $13.63 | 2019 | |
| Bardy Diagnostics, INC. | $13.00 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Terpstra listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.